Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 15/20 | 0.79 |
| ▸ | NMUR1 | Q9HB89 | 14/20 | 0.79 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.71 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604581 | 0.92 | NMUR2 (0.77) | NMUR2NMUR1OPRM1OPRD1OPRK1 | |
| SCHEMBL29494603 | 0.89 | NMUR2 (0.66) | NMUR2NMUR1NTSR2NTSR1NPY1R | |
| SCHEMBL29733484 | 0.89 | NTSR1 (0.69) | NMUR2NMUR1NTSR2NTSR1OPRM1 | |
| SCHEMBL29493537 | 0.89 | NTSR1 (0.70) | NMUR2NMUR1NTSR2NTSR1OPRM1 | |
| SCHEMBL29698606 | 0.89 | NMUR2 (0.71) | NMUR2NMUR1OPRM1OPRD1OPRK1 | |
| SCHEMBL29370026 | 0.89 | NMUR2 (0.71) | NMUR2NMUR1OPRM1OPRD1OPRK1 | |
| SCHEMBL3539226 | 0.89 | NMUR2 (0.71) | NMUR2NMUR1OPRM1OPRD1OPRK1 | |
| SCHEMBL29479234 | 0.87 | NTSR1 (0.66) | NMUR2NMUR1NTSR2NTSR1OPRM1 | |
| SCHEMBL8808113 | 0.86 | NMUR2 (0.70) | NMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL8808129 | 0.86 | NMUR2 (0.70) | NMUR2NMUR1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2026506334-A | — | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2026-02-24 | — | — | JP | disclosed |
| WO-2026013210-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-01-15 | — | — | WO | disclosed |
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-4648849-A1 | NMU RECEPTOR 2 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-4648849-A1 | NMU RECEPTOR 2 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2025-11-19 | — | — | EP | disclosed |
| CN-120603839-A | NMU receptor 2 agonists | 勃林格殷格翰国际有限公司 | 2025-09-05 | — | — | CN | disclosed |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-22 | — | — | US | disclosed |
| WO-2024149820-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024149820-A1 | NMU RECEPTOR 2 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-07-18 | — | — | WO | disclosed |
| US-20240167070-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-05-23 | — | — | US | disclosed |
| WO-2022186782-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Nγ-HYDROXY- OR Nγ-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-09 | — | — | WO | disclosed |
| US-20220213461-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-07 | — | — | US | disclosed |
| CN-106459160-B | ASX-specific protein ligases | 南洋理工大学 | 2022-03-29 | — | — | CN | disclosed |
| EP-3966321-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | Nanyang Technological University (SG) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015393-A1 | NOVEL NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, GPR18 | NMUR2 1/4885NMUR1 2/4885NTSR2 41/4885 |
| US-20240167070-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | ANPEP, DNPEP, ASNS | NMUR2 1038/4885NMUR1 890/4885NTSR2 330/4885 |
| US-20240279278-A1 | NMU RECEPTOR 2 AGONISTS | NMUR2, NMUR1, NMBR | NMUR2 1/4885NMUR1 2/4885NTSR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.